UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Androgen receptor antagonists for prostate cancer therapy

Endocrine-related cancer, 2014-08, Vol.21 (4), p.T105-T118

2014

Volltextzugriff (PDF)

Structure of the homodimeric androgen receptor ligand-binding domain

Nature communications, 2017-02, Vol.8 (1), p.14388-14388, Article 14388

2017

Volltextzugriff (PDF)

Emerging mechanisms of enzalutamide resistance in prostate cancer

Nature reviews. Urology, 2014-12, Vol.11 (12), p.712-716

2014

Volltextzugriff (PDF)

Glucocorticoid receptor triggers a reversible drug-tolerant dormancy state with acquired therapeutic vulnerabilities in lung cancer

Nature communications, 2021-07, Vol.12 (1), p.1-18, Article 4360

2021

Volltextzugriff (PDF)

TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth

eLife, 2019-12, Vol.8

2019

Volltextzugriff (PDF)

The Effect of F877L and T878A Mutations on Androgen Receptor Response to Enzalutamide

Molecular cancer therapeutics, 2016-07, Vol.15 (7), p.1702-1712

2016

Volltextzugriff (PDF)

Insights into Androgen Receptor Action in Lung Cancer

Endocrines, 2023-04, Vol.4 (2), p.269-280

2023

Volltextzugriff (PDF)

Ribosome impairment regulates intestinal stem cell identity via ZAKɑ activation

Nature communications, 2022-08, Vol.13 (1), p.4492-4492, Article 4492

2022

Volltextzugriff (PDF)

Inhibiting the Glucocorticoid Receptor to Enhance Chemotherapy Response

Journal of clinical oncology, 2023-10, Vol.41 (30), p.JCO2301195-4793

2023

Volltextzugriff (PDF)

Perturbations in 3D genome organization can promote acquired drug resistance

Cell reports (Cambridge), 2023-10, Vol.42 (10), p.113124-113124, Article 113124

2023

Volltextzugriff (PDF)

Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity

EMBO molecular medicine, 2023-12, Vol.15 (12), p.e17737-n/a

2023

Volltextzugriff (PDF)

Comparative genomic and transcriptomic analyses of LNCaP and C4-2B prostate cancer cell lines

PloS one, 2014-02, Vol.9 (2), p.e90002-e90002

2014

Volltextzugriff (PDF)

Proteomics on malignant pleural effusions reveals ERα loss in metastatic breast cancer associates with SGK1–NDRG1 deregulation

Molecular oncology, 2024-01, Vol.18 (1), p.156-169

2024

Volltextzugriff (PDF)

Genomic and epigenomic analysis of high-risk prostate cancer reveals changes in hydroxymethylation and TET1

Oncotarget, 2016-04, Vol.7 (17), p.24326-24338

2016

Volltextzugriff (PDF)

Duality of glucocorticoid action in cancer: tumor-suppressor or oncogene?

Endocrine-related cancer, 2021-06, Vol.28 (6), p.R157-R171

2021

Volltextzugriff (PDF)

The Role of Single Nucleotide Polymorphisms in Predicting Prostate Cancer Risk and Therapeutic Decision Making

BioMed research international, 2014-01, Vol.2014 (2014), p.1-16

2014

Volltextzugriff (PDF)

Estrogen Receptor on the move: Cistromic plasticity and its implications in breast cancer

Molecular aspects of medicine, 2021-04, Vol.78, p.100939-100939, Article 100939

2021

Volltextzugriff (PDF)

The complex landscape of luminal breast cancer

Endocrine-related cancer, 2024-10

2024

Volltextzugriff (PDF)

Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis

Nature (London), 2019-08, Vol.572 (7770), p.538-542

2019

Volltextzugriff (PDF)

Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond

Endocrine-related cancer, 2019-01, Vol.26 (1), p.R31-R52

2019

Volltextzugriff (PDF)

Differential transcriptional invasion signatures from patient derived organoid models define a functional prognostic tool for head and neck cancer

Oncogene, 2024-08, Vol.43 (32), p.2463-2474

2024

Volltextzugriff (PDF)

Unraveling the molecular interactions between α7 nicotinic receptor and a RIC3 variant associated with backward speech

Cellular and molecular life sciences : CMLS, 2024-12, Vol.81 (1), p.129-129, Article 129

2024

Volltextzugriff (PDF)

Crosstalk between glucocorticoid and mineralocorticoid receptors boosts glucocorticoid-induced killing of multiple myeloma cells

Cellular and molecular life sciences : CMLS, 2023-09, Vol.80 (9), p.249-249, Article 249

2023

Volltextzugriff (PDF)

Androgen and glucocorticoid receptor direct distinct transcriptional programs by receptor-specific and shared DNA binding sites

Nucleic acids research, 2021-04, Vol.49 (7), p.3856-3875

2021

Volltextzugriff (PDF)

The Tumor Coagulome as a Transcriptional Target and a Potential Effector of Glucocorticoids in Human Cancers

Cancers, 2023-02, Vol.15 (5), p.1531

2023

Volltextzugriff (PDF)

1 – 25 von 49

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(45)
Mit Volltextzugriff
(36)

Publikationsform

Artikel
(49)

Sprache

Englisch
(49)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Androgen receptor antagonists for prostate cancer therapy

Structure of the homodimeric androgen receptor ligand-binding domain

Emerging mechanisms of enzalutamide resistance in prostate cancer

Glucocorticoid receptor triggers a reversible drug-tolerant dormancy state with acquired therapeutic vulnerabilities in lung cancer

TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth

The Effect of F877L and T878A Mutations on Androgen Receptor Response to Enzalutamide

Insights into Androgen Receptor Action in Lung Cancer

Ribosome impairment regulates intestinal stem cell identity via ZAKɑ activation

Inhibiting the Glucocorticoid Receptor to Enhance Chemotherapy Response

Perturbations in 3D genome organization can promote acquired drug resistance

Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity

Comparative genomic and transcriptomic analyses of LNCaP and C4-2B prostate cancer cell lines

Proteomics on malignant pleural effusions reveals ERα loss in metastatic breast cancer associates with SGK1–NDRG1 deregulation

Genomic and epigenomic analysis of high-risk prostate cancer reveals changes in hydroxymethylation and TET1

Duality of glucocorticoid action in cancer: tumor-suppressor or oncogene?

The Role of Single Nucleotide Polymorphisms in Predicting Prostate Cancer Risk and Therapeutic Decision Making

Estrogen Receptor on the move: Cistromic plasticity and its implications in breast cancer

The complex landscape of luminal breast cancer

Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis

Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond

Differential transcriptional invasion signatures from patient derived organoid models define a functional prognostic tool for head and neck cancer

Unraveling the molecular interactions between α7 nicotinic receptor and a RIC3 variant associated with backward speech

Crosstalk between glucocorticoid and mineralocorticoid receptors boosts glucocorticoid-induced killing of multiple myeloma cells

Androgen and glucocorticoid receptor direct distinct transcriptional programs by receptor-specific and shared DNA binding sites

The Tumor Coagulome as a Transcriptional Target and a Potential Effector of Glucocorticoids in Human Cancers

Suchergebnisse filtern